{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:47:16Z","timestamp":1793659636289,"version":"4.5.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immune checkpoint blockade (ICB) immunotherapy has revolutionized cancer treatment, demonstrating exceptional clinical responses in a wide range of cancers. Despite the success, a significant proportion of patients still fail to respond, highlighting the existence of unappreciated mechanisms of immunotherapy resistance. Delineating such mechanisms is paramount to minimize immunotherapy failures and optimize the clinical benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we treated tumour-bearing mice with PD-L1 blockage antibody (aPD-L1) immunotherapy, to investigate its effects on cancer-induced emergency myelopoiesis, focusing on bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs). We examined the impact of aPD-L1 treatment on HSPC quiescence, proliferation, transcriptomic profile, and functionality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Herein, we reveal that aPD-L1 in tumour-bearing mice targets the HSPCs in the BM, mediating their exit from quiescence and promoting their proliferation. Notably, disruption of the PDL1\/PD1 axis induces transcriptomic reprogramming in HSPCs, observed in both individuals with Hodgkin lymphoma (HL) and tumour-bearing mice, shifting towards an inflammatory state. Furthermore, HSPCs from aPDL1-treated mice demonstrated resistance to cancer-induced emergency myelopoiesis, evidenced by a lower generation of MDSCs compared to control-treated mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings shed light on unrecognized mechanisms of action of ICB immunotherapy in cancer, which involves targeting of BM-driven HSPCs and reprogramming of cancer-induced emergency myelopoiesis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1386838","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:23:12Z","timestamp":1728620592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis"],"prefix":"10.3389","volume":"15","author":[{"given":"Athina","family":"Boumpas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis S.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Bousounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Grigoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bergo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iosif","family":"Papafragkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Iskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manousos","family":"Makridakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Vlachou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Hatzioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Mitroulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Trompouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis","family":"Verginis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14572","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice","author":"Lau","year":"2017","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8 T cells by \u03b1PD-L1 blockade","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","author":"Oh","year":"2020","journal-title":"Nat Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129353","article-title":"Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer","volume":"5","author":"Bar","year":"2020","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0537","article-title":"Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation","volume":"6","author":"Hartley","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e20633","article-title":"Neutrophil lymphocyte ratio (NLR) as a predictive biomarker for PD-1\/PD-L1 directed therapy in metastatic non-small cell lung cancer (NSCLC)","volume":"35","author":"Bumma","year":"2017","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn6173","article-title":"PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance","volume":"8","author":"van Gulijk","year":"2023","journal-title":"Sci Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-171089","article-title":"The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients","volume":"22","author":"Zhuo","year":"2018","journal-title":"Cancer biomark"},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41590-019-0555-2","article-title":"An intrinsic role of IL-33 in Treg cell\u2013mediated tumor immunoevasion","volume":"21","author":"Hatzioannou","year":"2020","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889075","article-title":"Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression","volume":"13","author":"Papafragkos","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-0716-1060-2_9","article-title":"Measuring suppressive activity and autophagy in myeloid-derived suppressor cells","volume":"2021","author":"Papaioannou","year":"2021","journal-title":"Methods Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1322","article-title":"Universal sample preparation method for proteome analysis","volume":"6","author":"Wi\u015bniewski","year":"2009","journal-title":"Nat Methods"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32556","article-title":"Proteome-based classification of nonmuscle invasive bladder cancer","volume":"146","author":"Stroggilos","year":"2020","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.3390\/jcm10163462","article-title":"Decoding the myeloid-derived suppressor cells in lymphoid Malignancies","volume":"10","author":"Papafragkos","year":"2021","journal-title":"J Clin Med Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0591-5","article-title":"Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90030-g","article-title":"RAG-1-deficient mice have no mature B and T lymphocytes","volume":"68","author":"Mombaerts","year":"1992","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-021-00707-9","article-title":"Chemotherapy-induced transposable elements activate MDA5 to enhance haematopoietic regeneration","volume":"23","author":"Clapes","year":"2021","journal-title":"Nat Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31727","article-title":"Soluble form of the MDA5 protein in human sera","volume":"10","author":"Okamoto","year":"2024","journal-title":"Heliyon"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-618090","article-title":"TGF-\u03b2 signaling in the control of hematopoietic stem cells","volume":"125","author":"Blank","year":"2015","journal-title":"Blood"},{"key":"B30","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/jca.65012","article-title":"Biomarkers for predicting the efficacy of immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR\u2013induced stop signal","volume":"10","author":"Fife","year":"2009","journal-title":"Nat Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103785","article-title":"PD-L1+ CD8+ T cells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance","volume":"25","author":"Zhen","year":"2022","journal-title":"Iscience"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49282-1","article-title":"Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development","volume":"15","author":"Varveri","year":"2024","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161594","article-title":"Maturation of hematopoietic stem cells from prehematopoietic stem cells is accompanied by up-regulation of PD-L1","volume":"215","author":"Tober","year":"2018","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2019.05.019","article-title":"TNF-\u03b1 coordinates hematopoietic stem cell survival and myeloid regeneration","volume":"25","author":"Yamashita","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Nasr","year":"2017","journal-title":"Sci Trans Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature07815","article-title":"IFN\u03b1 activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature09135","article-title":"Quiescent haematopoietic stem cells are activated by IFN-\u03b3 in response to chronic infection","volume":"465","author":"Baldridge","year":"2010","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3346","article-title":"Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal","volume":"18","author":"Pietras","year":"2016","journal-title":"Nat Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2017.06.013","article-title":"Pathogen-induced TLR4-TRIF innate immune signaling in hematopoietic stem cells promotes proliferation but reduces competitive fitness","volume":"21","author":"Takizawa","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0901-2","article-title":"S100A6 is a critical regulator of hematopoietic stem cells","volume":"34","author":"Grahn","year":"2020","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.3390\/cancers13153772","article-title":"Heterogeneous myeloid cells in tumors","volume":"13","author":"Dou","year":"2021","journal-title":"Cancers"},{"key":"B49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.15698\/cst","article-title":"Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression","volume":"3","author":"Sica","year":"2019","journal-title":"Cell Stress"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/cancers14071710","article-title":"Immunomodulatory properties of immune checkpoint inhibitors\u2014more than boosting T-cell responses","volume":"14","author":"Kuske","year":"2022","journal-title":"Cancers"},{"key":"B51","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","article-title":"Innate immune training of granulopoiesis promotes anti-tumor activity","volume":"183","author":"Kalafati","year":"2020","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports Malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108258","article-title":"PD-L1 reverse signaling in dermal dendritic cells promotes dendritic cell migration required for skin immunity","volume":"33","author":"Lucas","year":"2020","journal-title":"Cell Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302461","article-title":"PD-L1 regulates inflammatory macrophage development from human pluripotent stem cells by maintaining interferon-gamma signal","volume":"6","author":"Cao","year":"2022","journal-title":"Life Science Alliance"},{"key":"B55","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.stem.2018.01.017","article-title":"CD150high bone marrow Tregs maintain hematopoietic stem cell quiescence and immune privilege via adenosine","volume":"22","author":"Hirata","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169516","article-title":"Memory CD8+ T cells support the maintenance of hematopoietic stem cells in the bone marrow","volume":"103","author":"Geerman","year":"2018","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3061","article-title":"Cross-talk between T cells and hematopoietic stem cells during adoptive cellular therapy for Malignant glioma","volume":"24","author":"Wildes","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205085120","article-title":"Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity","volume":"120","author":"Zhang","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577655","article-title":"CD80 on human T Cells is associated with FoxP3 expression and supports treg homeostasis","volume":"11","author":"Soskic","year":"2021","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.6.3180","article-title":"CD80+ Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis","volume":"169","author":"Mencacci","year":"2002","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00327","article-title":"The role of dendritic cell maturation in the induction of insulin-dependent diabetes mellitus","volume":"8","author":"Mbongue","year":"2017","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222451","article-title":"Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors","volume":"81","author":"Benesova","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4+ T cells are essential for the development of destructive thyroiditis induced by anti\u2013PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731947","article-title":"Regulatory T cells in autoimmunity and cancer: a duplicitous lifestyle","volume":"12","author":"Hatzioannou","year":"2021","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B66","unstructured":"PD-L1 blockade immunotherapy rewires cancer emergency myelopoiesis\n            BoumpasA\n          2023"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1386838\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:23:21Z","timestamp":1728620601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1386838\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2024.1386838"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1386838","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"article-number":"1386838"}}